Radnostix Q3 Revenue Drops 22% as Cobalt Contract Delays Bite
INIS sits 27% above its 52-week low of $0.03 on light trading volume (0.1× avg).
Summary
Q3 revenue fell 22% year over year to $2.57 million, driven by delays in large Cobalt Products contracts awaiting NRC amendments and a global cobalt-57 raw material supply interruption that cut Calibration & Reference Products sales. Gross profit came in at $1.51 million, and Theranostics Products sales rose 15% year over year as customers returned after earlier recall disruptions. The results follow the 10-Q filed today showing a $842K Q3 loss, a $3.07M nine-month loss, and cash down to $711K, leaving the pending DUF6 asset sale as the main liquidity backstop. Radnostix expects to execute the delayed cobalt contracts in Q1 2027 pending NRC amendments and aims to close the $13.5 million DUF6 sale to Nano Nuclear Energy, also subject to NRC approval.
At the time of this announcement, INIS was trading at $0.04 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $20.4M. The 52-week trading range was $0.03 to $0.11. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.